N30 Pharmaceuticals Announces Name Change to Nivalis Therapeutics

BOULDER, Colo., Feb. 24, 2015 /PRNewswire/ -- N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc.  The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).

The new corporate name, Nivalis Therapeutics, originated from one of the Company's own scientists, and is derived from the Latin term for 'of snow.'  Just as each snowflake is unique, so too is each person with CF. With more than 1,800 known mutations of the gene responsible for CF, treating the disease requires solutions as unique as snowflakes.

"The organization has transitioned from an early-stage Company focused on research to a clinical-stage Company that is now focused on translating precision-based scientific discoveries into patient benefit," said Jon Congleton, president and chief executive officer of Nivalis Therapeutics. "As part of this evolution, we believe that it is important for the Company name to better articulate the commitment, passion and energy that we are bringing to the cystic fibrosis community as we strive to develop and bring to market innovative solutions that may improve and extend the lives of people managing this disease."

About N91115

N91115 is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR). Nivalis Therapeutics recently completed a Phase 1 dose-escalation trial of orally administered N91115 in healthy volunteers.   No dose limiting toxicities were identified by the safety monitoring committee for the trial.

A trial in CF patients homozygous for the F508del-CFTR mutation is now underway. In pre-clinical studies, N91115 has been shown to increase the function of F508del-CFTR, the mutant protein that is estimated to be present in approximately 86 percent of people with CF in the United States and Europe.

About Cystic Fibrosis

CF is a life-threatening, genetic disease that primarily affects the lungs and digestive system. According to the Cystic Fibrosis Foundation (www.cff.org), an estimated 30,000 children and adults in the United States and 70,000 people worldwide have CF. CF is characterized by a defect in the chloride channel of human cells known as the "cystic fibrosis transmembrane conductance regulator," or CFTR, which is caused by a genetic mutation. CFTR is critical for the adequate hydration of the lungs and other organs of the body. Researchers have identified more than 1,800 mutations in the CF gene, and it is estimated that approximately 47 percent of people with CF in the United States have two copies of the F508del-CFTR mutation, and an additional 39 percent have one copy of this mutation. As a consequence of the F508del mutation, the CFTR protein is defective and fails to result in fluid movement.  With N91115, Nivalis Therapeutics aims to increase CFTR function and restore proper hydration to critical organs, particularly the lungs.

About Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. (www.nivalis.com) is a privately held, clinical-stage pharmaceutical company headquartered in Boulder, Colorado. Nivalis Therapeutics is dedicated to making a difference in the lives of patients with cystic fibrosis and their families.

Media Contact:
Lindsay Rocco
1-862-596-1304
[email protected]

SOURCE Nivalis Therapeutics, Inc.

Related Links

http://www.nivalis.com